TSVT Analyst Price Targets - Benzinga

SPY769.86+0.03%QQQ749.55−0.00%BTC/USD86,774.80+0.30%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

TSVT

TSVTNasdaq Private Market

Private market price is not available

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

TSVT Analyst Price Targets - Benzinga

TSVT Analyst Price Targets

Wall Street analyst price targets and consensus rating for TSVT (TSVT).

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

2Buy

3Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$8

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 14, 2025	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$6→$5
Mar 11, 2025	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$9→$5
Jul 29, 2024	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$7→$6
Jun 27, 2024	Wedbush	David Nierengarten	Maintained	Neutral	$5
May 9, 2024	Canaccord Genuity	John Newman	PT Cut	Buy	$12→$11
Apr 8, 2024	Citigroup	Samantha Semenkow	PT Raise	Buy	$9→$12
Mar 18, 2024	Wedbush	David Nierengarten	Maintained	Neutral	$5
Jan 31, 2024	Leerink Partners	Daina Graybosch	Upgrade	Market Perform→Outperform	$5→$18
Jan 31, 2024	TD Cowen	Yaron Werber	Downgrade	Outperform→Market Perform	—
Nov 20, 2023	Wedbush	David Nierengarten	Downgrade	Outperform→Neutral	$2
Oct 30, 2023	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	—
Oct 12, 2023	Citigroup	Samantha Semenkow	Initiate	Buy	$13

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on 2seventy bio, Lowers Price Target to $5

Morgan Stanley analyst Matthew Harrison maintains 2seventy bio (NASDAQ:TSVT) with a Equal-Weight and lowers the price target from $6 to $5.

Benzinga Newsdesk

This Lennar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
Leerink Partners Downgrades 2seventy bio to Market Perform, Lowers Price Target to $5

Leerink Partners analyst Daina Graybosch downgrades 2seventy bio (NASDAQ:TSVT) from Outperform to Market Perform and lowers the price target from $9 to $5.

Benzinga Newsdesk

US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal'

U.S. stock futures rose on Tuesday following Monday's heavy selloff. Futures of all four benchmark indices surged in premarket trading.

Rishabh Mishra

PRO
Morgan Stanley Maintains Equal-Weight on 2seventy bio, Lowers Price Target to $6

Morgan Stanley analyst Matthew Harrison maintains 2seventy bio (NASDAQ:TSVT) with a Equal-Weight and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
Wedbush Reiterates Neutral on 2seventy bio, Maintains $5 Price Target

Wedbush analyst David Nierengarten reiterates 2seventy bio (NASDAQ:TSVT) with a Neutral and maintains $5 price target.

Benzinga Newsdesk